Phreesia, Inc. (NYSE:PHR – Get Free Report) General Counsel Allison C. Hoffman sold 4,585 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $26.90, for a total value of $123,336.50. Following the completion of the transaction, the general counsel now owns 154,552 shares of the company’s stock, valued at $4,157,448.80. The trade was a 2.88 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Phreesia Stock Performance
Shares of NYSE PHR traded up $0.44 during mid-day trading on Friday, reaching $27.24. 309,924 shares of the company were exchanged, compared to its average volume of 382,284. The stock has a market capitalization of $1.58 billion, a P/E ratio of -18.53 and a beta of 0.94. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The company’s 50-day simple moving average is $23.42 and its 200-day simple moving average is $22.77. Phreesia, Inc. has a twelve month low of $17.07 and a twelve month high of $29.16.
Phreesia (NYSE:PHR – Get Free Report) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The firm had revenue of $106.80 million for the quarter, compared to analysts’ expectations of $106.33 million. During the same period in the prior year, the firm earned ($0.58) EPS. The business’s revenue was up 16.6% on a year-over-year basis. As a group, research analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.
Institutional Trading of Phreesia
Analyst Ratings Changes
Several brokerages recently commented on PHR. JMP Securities reissued a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Citigroup increased their price objective on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. Truist Financial boosted their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and increased their price target for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, KeyCorp lifted their price objective on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, January 8th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $31.00.
Read Our Latest Stock Analysis on PHR
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Read More
- Five stocks we like better than Phreesia
- Expert Stock Trading Psychology Tips
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- How to Calculate Stock Profit
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Health Care Stocks Explained: Why You Might Want to Invest
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.